In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Abstract Text:

Sherie Masse,Xiaozhi Lu,Tatyana Dekhtyar,Liangjun Lu,Gennadiy Koev,Feng Gao,Hongmei Mo,Dale Kempf,Barry Bernstein,George J Hanna,Akhteruzzaman Molla,Sherie Masse,Xiaozhi Lu,Tatyana Dekhtyar,Liangjun Lu,Gennadiy Koev,Feng Gao,Hongmei Mo,Dale Kempf,Barry Bernstein,George J Hanna,Akhteruzzaman Molla,

Lopinavir (LPV)-ritonavir has demonstrated durable antiviral activity in human immunodeficiency virus type 1 (HIV-1)-infected antiretroviral-naïve and protease inhibitor (PI)-experienced patients. However, information on LPV activity against HIV-2 and the patterns of mutations in HIV-2 in response to selection by LPV is limited. The activity of LPV against three strains of HIV-2 was assessed and compared to activity against a reference HIV-1 strain. LPV demonstrated activity similar to that observed against HIV-1 in two HIV-2 strains (HIV-2(MS) and HIV-2(CBL-23)) tested. On the other hand, approximately 10-fold-reduced susceptibility was observed with the third HIV-2 strain, HIV-2(CDC310319). Passage of HIV-2(MS) with increasing concentrations of LPV selected mutations V47A and D17N in the HIV-2 protease gene. The introduction of both 17N and 47A either individually or together into HIV-2(ROD) molecular infectious clones showed that the single V47A substitution in HIV-2 resulted in a substantial reduction in susceptibility to LPV. In contrast, this mutant retained wild-type susceptibility to other PIs and appeared to be hypersusceptible to atazanavir and saquinavir.

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Publishing Authors By Initials

S Masse,X Lu,T Dekhtyar,L Lu,G Koev,F Gao,H Mo,D Kempf,B Bernstein,GJ Hanna,A Molla,S Masse,X Lu,T Dekhtyar,L Lu,G Koev,F Gao,H Mo,D Kempf,B Bernstein,GJ Hanna,A Molla,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Antimicrobial agents and chemotherapy

VOLUME: 51

Page Numbers: 3075-80

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 18

MONTH: 06

YEAR: 2007

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

AFFILIATION: Antiviral Research, Global Pharmaceutical Research and Development, AP52N-1 Rm. 1133, 200 Abbott Park Road, Abbott Park, IL 60064, USA. Sherie.masse@abbott.com

Country: United States

AGENCY: United States NIGMS

GRANT: GM 065057

ACRONYM: GM

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir Related Publications

• A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.
• Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
• Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, a-790742.
• Compensatory evolution of interacting gene products through multifunctional intermediates.
• Does red blood cell distribution width (RDW) improve evaluation of microcytic anaemias?
• Engineering the properties of d-amino Acid oxidases by a rational and a directed evolution approach.
• Enhancement of bioseparation and dewaterability of domestic wastewater sludge by fungal treated dewatered sludge.
• Evaluation of fungal potentiality for bioconversion of domestic wastewater sludge.
• Glycine oxidase from Bacillus subtilis: Role of Histidine 244 and Methionine 261.
• Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
• Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.
• In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
• Optimization of glutaryl-7-aminocephalosporanic acid acylase expression in E. coli.
• Prevalence of iron deficiency anaemia in children of the urban slums of Karachi.
• Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
• Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.
• Risk factors for nutritional rickets among children in Kuwait.
• Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.
• [Case Imaging: 3. Pulmonary nocardiosis.]
• [Not Available.]
• [Pulmonary candidiasis in a non-immunodepressed patient.]